These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7535070)

  • 21. A phase II study of recombinant human granulocyte-colony stimulating factor (rHuG-CSF, lenograstim) in the treatment of agranulocytosis in children.
    Donadieu J; Boutard P; Tchernia G; Oster G; Gordon-Smith EC; Philippe N; Le Gall E; Nivelon JL; Dopfer P; Babin-Boilletot A
    Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):441-8. PubMed ID: 7538658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
    Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
    Elias AD; Skarin AT; Richardson P; Ibrahim J; McCauley M; Frei E
    Biol Blood Marrow Transplant; 2002; 8(6):326-33. PubMed ID: 12108918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.
    Dunn CJ; Goa KL
    Drugs; 2000 Mar; 59(3):681-717. PubMed ID: 10776839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer.
    Drummond M; Davies L
    Pharmacoeconomics; 1994; 6 Suppl 2():44-52. PubMed ID: 10155594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study.
    Gatzemeier U; Kleisbauer JP; Drings P; Kaukel E; Samaras N; Melo MJ; Cardenal F; Robinet G; Snijder RJ; von Pawel J; Palisses R
    Am J Clin Oncol; 2000 Aug; 23(4):393-400. PubMed ID: 10955871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoeconomic evaluation of lenograstim. Conclusions and future directions.
    Menzin J; Oster G; Cour-Chabernaud V; Richard D
    Pharmacoeconomics; 1994; 6 Suppl 2():53-60. PubMed ID: 10155595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of the lenograstim pharmacoeconomics programme.
    Oster G; Menzin J; Richard D; Cour-Chabernaud V
    Pharmacoeconomics; 1994; 6 Suppl 2():9-17. PubMed ID: 10155596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS).
    Chevreau C; Bui BN; Chevallier B; Krakowski I; Maugard C; Mihura J; Coindre JM; Gil B; Cour-Chabernaud V
    Am J Clin Oncol; 1999 Jun; 22(3):267-72. PubMed ID: 10362334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose intensification of chemotherapy and the role of granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor in small cell lung cancer.
    Tjan-Heijnen VC; Postmus PE; Wagener DJ
    Anticancer Drugs; 1997 Jul; 8(6):549-64. PubMed ID: 9300569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of lenograstim (glycosylated rHuG-CSF) in the treatment of inflammatory breast cancer for Germany and Italy.
    Mapelli V; Graf vond der Schulenburg JM; Laaser U; Allhoff PG; Rossi F
    Pharmacoeconomics; 1994; 6 Suppl 2():27-35. PubMed ID: 10155593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increasing the dose intensity of chemotherapy by means of granulocyte-colony stimulating factor (G-CSF) support in the treatment of small cell lung cancer (SCLC).
    Girling DJ; Thatcher N; Clark PI; Stephens RJ
    Eur J Cancer; 1996 Jun; 32A(7):1263. PubMed ID: 8758266
    [No Abstract]   [Full Text] [Related]  

  • 35. Colony stimulating factors: G-CSFs--filgrastim (Neupogen) and lenograstim (Granocyte).
    MacConnachie AM
    Intensive Crit Care Nurs; 1998 Feb; 14(1):49-50. PubMed ID: 9652261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose chemotherapy in small cell lung cancer.
    Pasini F; Pelosi G; De Manzoni G; Rosti G
    Tumori; 2002; 88(3):179-86. PubMed ID: 12195754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy dose intensity in small cell lung cancer.
    Souhami RL; De Elvira MC
    Lung Cancer; 1994 Mar; 10 Suppl 1():S175-85. PubMed ID: 8087508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis.
    Berghmans T; Paesmans M; Lafitte JJ; Mascaux C; Meert AP; Sculier JP
    Lung Cancer; 2002 Aug; 37(2):115-23. PubMed ID: 12140132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ninth Biannual Report of the Cochrane Haematological Malignancies Group--focus on hematopoietic growth factors.
    Skoetz N; Weingart O; Monsef I; Bauer K; Brillant C; Herbst C; Kluge S; Engert A;
    J Natl Cancer Inst; 2009 May; 101(9):E1. PubMed ID: 19401542
    [No Abstract]   [Full Text] [Related]  

  • 40. The importance of dose and schedule in chemotherapy for small cell lung cancer.
    Ranson M; Thatcher N
    Anticancer Drugs; 1995 Oct; 6 Suppl 5():53-63. PubMed ID: 8845495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.